86results about How to "Reduce lipid accumulation" patented technology

The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract and Mori Folium extract, and a method for suppressing obesity using the composition. Further, the present invention provides an antiobesity composition comprising extract of Melissa, extract of Artemisia and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract, Artemisia extract and Mori Folium extract, and a method for suppressing obesity using the composition. When the present compositions are administrated into genetically obese mice or high fat diet-induced obese mice, the present compositions reduced body weight, body fat and gonadal fat, and reduce blood cholesterol level and obesity-related blood glucose level. Also, the present compositions suppress hypertrophy of adipocytes, and inhibit the accumulation of lipid in the liver by reducing the size and number of lipid vacuoles. Furthermore, in human clinial trial the present compositions show that body weight, PIBW, body fat, especially visceral fat, apolipoprotin B concentration, ratio of total cholesterol/HDL cholesterol and ratio of LDL cholesterol/HDL cholesterol are significantly decreased, and atherogenic index is improved and muscle mass is increased. Thus, the present compositions can be usefully applied as antiobesity composition for reduction of body weight and suppression of abdominal fat, particularly, visceral fat.

The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.

The present invention provides compositions and methods for identifying a subject as having a genetic predisposition to obesity or at risk of developing obesity. The present invention also provides compositions and methods for expressing a CREBRF polypeptide of the invention in a cell or precursor thereof and cells expressing a nucleic acid molecule encoding a CREBRF polypeptide of the invention.

Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia are provided herein. Such compositions can contain synergizing amounts of leucine and/or one or more leucine metabolites in combination with nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and with at least one or more anti-diabetic agents. Such compositions can contain sub-therapeutic amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and/or sub-therapeutic amounts of one or more anti-diabetic agents that can achieve the same therapeutic efficacy as therapeutic amounts of said compositions in diabetes and/or hyperlipidemia medicaments. The composition can also reduce the side effects associated with treatment using anti-diabetic agents and/or nicotinic acid.

A peptide has the formula (I) R₁—W_m—X_n-AA₁-AA₂-AA₃-Y_p—Z_q—R₂, where AA₁ is Tyr or Trp, AA₂ is Val, Ile, Leu or Met, AA₃ is Tyr, Phe or Trp, W, X, Y and Z are amino acids, m, n, p and q are each 0 or 1, and m+n+p+q is less than or equal to 2. R₁ is H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, aralkyl, or R₅—CO—. R₅ is H, a non-cyclic aliphatic group, alicyclyl, aryl, aralkyl, heterocyclyl or heteroarylalkyl. R₂ is —NR₃R₄, —OR₃, or —SR₃. R₃ and R₄ are each H, a polymer derived from polyethylene glycol, a non-cyclic aliphatic group, alicyclyl, heterocyclyl, heteroarylalkyl, aryl, or aralkyl. R₁ and R₂ are not amino acids. Cosmetic or pharmaceutical compositions may include the peptide. It find use in reduction of lipid accumulation in the skin, treatment of cellulite, and treatment of symptoms of skin aging.

The invention relates to the use of a composition comprising probiotic bacteria that regulate expression of key components involved in diet-induced insulin resistance for ameliorating or preventing diet-induced insulin resistance. The use of the probiotic strain and/or a fraction of said strain and/or metabolite of said strain for the manufacture of a medicament or a food or feed product to ameliorate diet-induced insulin resistance and help to obtain optimal body weight of a mammal is disclosed. Preferably, the composition comprises at least one probiotic Lactobacillus acidophilus strain and/or a fraction of said strain and/or metabolite of said strain for ameliorating or preventing diet-induced insulin resistance, said composition characterized by up-regulating expression of the ANGPTL4 gene encoding for FIAF in the intestine, down-regulating expression of the Elovl6 gene in the intestine as well as down-regulating expression of the SCD1 gene in skeletal muscles of a mammal, and wherein the probiotic strain is selected from the group of strains consisting of Lactobacillus acidophilus strain LA-5 (DSM13241).

The invention discloses an application of pulsatilla saponin B4 in preparation of a medicine for treating non-alcoholic fatty liver disease. As the cell and molecular mechanism of the liver injury of the non-alcoholic fatty liver disease is not very clear yet, and an effective drug treatment method for the non-alcoholic fatty liver disease is lacked, so that positive exploration of safe and effective drug treatment is a current research hotspot. The curative effect and the safety of the existing medicine need to be further improved or verified. The invention discloses a novel medicine for treating non-alcoholic fatty liver disease, the active ingredient is pulsatilla saponin B4, experiments prove that the pulsatilla saponin B4 can effectively reduce lipid accumulation of rat liver caused by high fat diet, the curative effect is equivalent to that of a positive control medicine, the side effect of hepatotoxicity caused by fenofibrate can be avoided, and therefore, the pulsatilla saponin B4 can be used for preventing and treating non-alcoholic fatty liver disease (NAFLD).

Provided is a method of a method of preparing a Rosa laevigata fruit extract which regulates CD36, ApoA1, and SRB1, including extracting the fruit of Rosa laevigata using water, alcohols, or mixtures of water and alcohols as solvents. Also provided is a method of regulating CD36, ApoA1, and SRB1, including administering to a subject a composition containing an effective amount of the Rosa laevigata fruit extract. By suppressing the gene expression of CD36 and enhancing the gene expression of ApoA1 and SRB1, the Rosa laevigata fruit extract may be used to regulate lipid metabolism and reduce liver lipid accumulation and blood lipid levels.

The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.

The invention discloses a mulberry bud tea, which is made by taking local purely natural non-pollution mulberry buds as a principal raw material with compatibility of the eucommia buds and the Salvia miltiorrhiza buds through ancient tea frying skill and modern braking process. The tea contains various amion acids which comprise 18 essential amion acids for human body, fat, vitamins C, B1, B2 and folic acid, renieratene, calcium, phosphorus, iron, manganese, sodium and large quantities of flavonoids. The tea has effects of anti-stress, anti-aging, improving the body endurance, reducing the serum cholesterol and regulating the adrenergic function. Regularly drinking the mulberry bud tea has the effects of improving eyesight, reducing lipid retention in the body and decreasing the blood fat and blood sugar levels.

The invention discloses a traditional Chinese medicine composition for losing weight. The traditional Chinese medicine composition is prepared from, by weight, 10-30 parts of fructus crataegi, 10-20 parts of radix puerariae, 10-15 parts of pinenut kernels,9-17 parts of pericarpium citri reticulatae, 8-14 parts of radix codonopsis, 8-12 parts of semen cassia, 7-12 parts of fructus forsythia, 6-10 parts of folium sennae, 6-9 parts of rhizoma atractylodis macrocephalae, 5-10 parts of herba dendrobii, 5-9 parts of semen plantaginis and 3-6 parts of herba taraxac. The selected materials are natural and environmentally friendly, the traditional Chinese medicine composition can reduce phlegm, eliminate fat, invigorate the spleen and eliminate dampness and regulate functional activities of qi, can effectively clear heat in the human body, reduce lipid deposition reduction in the human body and discharge toxin in the human body and is free of side effect on the human body, suitable for treating female obesity, simple in formula, low in cost and definite in curative effect, a patient is free of side effects of anorexia, diarrhea and the like, nourishing and weight losing are achieved, and immunity of the organism is improved.

The invention belongs to the technical field of health care, and particularly relates to a seaweed fruit and vegetable formula assisting in reducing fat and losing weight. The seaweed fruit and vegetable formula comprises the following components in percentage by mass of 95-96% of sargassum fusiforme, 2-3% of a turmeric extract and 1-2% of pomegranate rind extract. The turmeric extract and the pomegranate rind extract are compounded in the sargassum fusiforme, natural active substances in seaweed and fruits and vegetables are fully utilized, the effect of assisting in reducing fat and losing weight is achieved, and the utilization rate of natural resources is further increased. Meanwhile, the natural properties of the seaweed fruits and vegetables can greatly reduce the toxic and side effects caused by synthetic substances, and the natural products from the seaweed fruits and vegetables are safe, non-toxic and harmless, can achieve the purpose of assisting in reducing fat and losing weight, and can improve the health condition of people.

The invention discloses an application of buddle jasaponin IV in preparation of medicine for treating the non-alcoholic fatty liver disease and the insulin resistance diseases. The tests show that in the application process, the buddle jasaponin IV has a remarkable effect of improving the non-alcoholic fatty liver, the mechanism of the buddle jasaponin IV is related with an anti-oxidative stress effect and the improvement on the insulin resistance, and therefore the buddle jasaponin IV can be used for treating the other diseases related with insulin resistance.

The invention belongs to the field of feed development and specifically relates to piglet feed and a preparation method thereof. The piglet feed includes the following constituents in parts by weight:cordyceps medium residues 25-45, mulberry leaves 10-15, corn 10-15, fine rice bran 10-13, fish meal 5-8, soybean meal 5-8, biological enzymes 1-5 and premix 4-8. The cordyceps medium residues are pre-treated as follows: performing water steaming at a temperature of 60 DEG C to 100 DEG C and then performing ultraviolet irradiation for 20min to 50min. The formula of the piglet feed provided by theinvention not only reduces feed cost, but also can improve the feed absorption-utilization rate of piglets; and the addition of the biological enzymes can not only enzymatically decompose the cordyceps medium residues but also perform enzymolysis on other components like the corn, the fine rice bran, the fish meal and the soybean meal of the constituents so as to make up for insufficient starch utilization of the piglets in a weaning period.

The invention belongs to the field of health foods and discloses health maintenance noodles with effects of losing weight and reducing fat. The noodles comprise the following components in parts by weight: 5-10 parts of chromium-enriched eggs, 20-40 parts of chromium-enriched pumpkin, 10-20 parts of lotus leaves, 100-150 parts of high gluten wheat flour, 10-15 parts of corn flour, 1-3 parts of edible salt, 0.1-0.3 part of dietary alkali and 50-70 parts of water. The health maintenance noodles can achieve effects of inhibiting weight increase, lowering serum cholesterol and triglyceride contentand improving the high density lipoprotein cholesterol level, so that the effects of losing weight and reducing fat are achieved.

The present invention discloses an application of a pleurotus eryngii mycelium polysaccharide from solid-state fermentation (PESF). The active polysaccharide (PESF) with a hypolipidemic function is produced by a solid-state fermentation method of pleurotus eryngii mycelia. In a mouse model in vivo hypolipidemic mechanism, an oral administration of a certain dose of the PESF can regulate intestinalmicroflora, significantly promotes growth of Lactobacillus and inhibits major micro-organism genus of staphylococcus, corynebacterium, aerococcus, etc., thus restores intestinal flora imbalance caused by a high-fat diet to a certain degree, finally inhibits absorption of exogenous lipids in intestinal tract, and thus reduces accumulation of blood lipids and liver lipids in body. The pleurotus eryngii polysaccharide is analyzed and confirmed to have biofunctional activity of regulating structure and functions of the intestinal microflora, and a significant correlation is found between polysaccharide hypolipidemic activity and polysaccharide intestinal microflora-regulating function.

The present disclosure provides a method of treating a nonalcoholic fatty liver disease in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.

The invention belongs to the technical field of application of monomeric compounds, and particularly relates to application of [7-(2,2-dimethylbut-3-enamido)-2,4-dimethyl-5-oxo-1,2,3,4,4a,5,6,10b-octahydrobenzo[f] quinolin-1-yl acetate, DQA] in preparation of drugs for lowering lipid and treating obesity. In-vitro and in-vivo lipid-lowering experimental model research finds that the [7-(2,2-dimethylbut-3-enamido)-2,4-dimethyl-5-oxo-1,2,3,4,4a,5,6,10b-octahydrobenzo[f] quinolin-1-yl acetate, DQA] has the activity of reducing fat accumulation and lowering blood fat, can be used for preparing drugs for lowering lipid and treating obesity, is suitable for large-scale popularization and has potential application value.